NeueHealth Net Worth
NeueHealth Net Worth Breakdown | NEUE |
NeueHealth Net Worth Analysis
NeueHealth's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including NeueHealth's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of NeueHealth's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform NeueHealth's net worth analysis. One common approach is to calculate NeueHealth's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares NeueHealth's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing NeueHealth's net worth. This approach calculates the present value of NeueHealth's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of NeueHealth's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate NeueHealth's net worth. This involves comparing NeueHealth's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into NeueHealth's net worth relative to its peers.
Enterprise Value |
|
To determine if NeueHealth is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding NeueHealth's net worth research are outlined below:
| NeueHealth had very high historical volatility over the last 90 days | |
| NeueHealth has a very high chance of going through financial distress in the upcoming years | |
| NeueHealth was previously known as Bright Health Group and was traded on New York Stock Exchange under the symbol BHG. | |
| The company reported the previous year's revenue of 1.16 B. Net Loss for the year was (1.15 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| NeueHealth generates negative cash flow from operations | |
| NeueHealth has a frail financial position based on the latest SEC disclosures | |
| About 64.0% of the company shares are owned by institutional investors | |
| Latest headline from prnewswire.com: ATHLETICA SPORT SYSTEMS INC. STELLT DAS NEUE LIVE-GESTEUERTE DIGITALE DASHERBOARD-SYSTEM CRYSTAPLEX VOR |
NeueHealth uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in NeueHealth. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to NeueHealth's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow NeueHealth's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 52.8 M.Market Cap |
|
Project NeueHealth's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.02) | (0.97) | |
| Return On Capital Employed | 3.48 | 3.65 | |
| Return On Assets | (0.94) | (0.89) | |
| Return On Equity | 3.35 | 3.52 |
When accessing NeueHealth's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures NeueHealth's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of NeueHealth's profitability and make more informed investment decisions.
Please note, the presentation of NeueHealth's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, NeueHealth's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of NeueHealth's management manipulating its earnings.
Evaluate NeueHealth's management efficiency
NeueHealth has return on total asset (ROA) of (0.0358) % which means that it has lost $0.0358 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8326) %, meaning that it created substantial loss on money invested by shareholders. NeueHealth's management efficiency ratios could be used to measure how well NeueHealth manages its routine affairs as well as how well it operates its assets and liabilities. At present, NeueHealth's Return On Equity is projected to increase slightly based on the last few years of reporting. At present, NeueHealth's Intangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.32, whereas Non Current Assets Total are forecasted to decline to about 129.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (32.01) | (30.41) | |
| Tangible Book Value Per Share | (43.73) | (41.55) | |
| Enterprise Value Over EBITDA | (0.61) | (0.64) | |
| Price Book Value Ratio | (0.19) | (0.20) | |
| Enterprise Value Multiple | (0.61) | (0.64) | |
| Price Fair Value | (0.19) | (0.20) | |
| Enterprise Value | 1.4 B | 1.3 B |
NeueHealth benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Revenue 1.2 B | Quarterly Revenue Growth 0.286 | Revenue Per Share 145.939 | Return On Equity (1.83) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NeueHealth insiders, such as employees or executives, is commonly permitted as long as it does not rely on NeueHealth's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NeueHealth insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
NeueHealth Corporate Filings
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 8th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
10Q | 13th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
NeueHealth Earnings per Share Projection vs Actual
NeueHealth Corporate Management
| Jeff Craig | General Secretary | Profile | |
| Jeffrey Scherman | Chief Officer | Profile | |
| Jay Matushak | Chief Officer | Profile | |
| Tomas Orozco | Executive Care | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeueHealth. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For information on how to trade NeueHealth Stock refer to our How to Trade NeueHealth Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeueHealth. If investors know NeueHealth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeueHealth listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Revenue Per Share 145.939 | Quarterly Revenue Growth 0.286 | Return On Assets (0.04) | Return On Equity (1.83) |
The market value of NeueHealth is measured differently than its book value, which is the value of NeueHealth that is recorded on the company's balance sheet. Investors also form their own opinion of NeueHealth's value that differs from its market value or its book value, called intrinsic value, which is NeueHealth's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeueHealth's market value can be influenced by many factors that don't directly affect NeueHealth's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeueHealth's value and its price as these two are different measures arrived at by different means. Investors typically determine if NeueHealth is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeueHealth's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.